MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

A

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Search

Charles River Laboratories International Inc

Abrir

SetorSaúde

173.09 -0.32

Visão Geral

Variação de preço das ações

24h

Atual

Mín

169.24

Máximo

178.85

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+19.36% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-78M

7.9B

Abertura anterior

173.41

Fecho anterior

173.09

Sentimento de Notícias

By Acuity

11%

89%

16 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de abr. de 2026, 22:56 UTC

Notícias Principais

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 de abr. de 2026, 20:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 de abr. de 2026, 23:55 UTC

Conversa de Mercado

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 de abr. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 de abr. de 2026, 23:23 UTC

Notícias Principais

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 de abr. de 2026, 23:07 UTC

Ganhos

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 de abr. de 2026, 23:02 UTC

Notícias Principais

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 de abr. de 2026, 23:00 UTC

Notícias Principais

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 de abr. de 2026, 23:00 UTC

Notícias Principais

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 de abr. de 2026, 23:00 UTC

Notícias Principais

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 de abr. de 2026, 22:39 UTC

Ganhos

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 de abr. de 2026, 22:08 UTC

Conversa de Mercado

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 de abr. de 2026, 22:00 UTC

Notícias Principais

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 de abr. de 2026, 22:00 UTC

Notícias Principais

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 de abr. de 2026, 22:00 UTC

Notícias Principais

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 de abr. de 2026, 22:00 UTC

Notícias Principais

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 de abr. de 2026, 22:00 UTC

Notícias Principais

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 de abr. de 2026, 22:00 UTC

Notícias Principais

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 de abr. de 2026, 22:00 UTC

Notícias Principais

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 de abr. de 2026, 21:56 UTC

Aquisições, Fusões, Aquisições de Empresas

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 de abr. de 2026, 21:31 UTC

Notícias Principais

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

1 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

1 de abr. de 2026, 20:38 UTC

Ganhos

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 de abr. de 2026, 20:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 de abr. de 2026, 20:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 de abr. de 2026, 20:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 de abr. de 2026, 20:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 de abr. de 2026, 20:07 UTC

Conversa de Mercado

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 de abr. de 2026, 20:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

19.36% parte superior

Previsão para 12 meses

Média 205.89 USD  19.36%

Máximo 265 USD

Mínimo 175 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

8

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

16 / 349 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat